- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.08. | Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss | ||
| 18.08. | BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca | ||
| 17.08. | Regeneron ends eye disease trial for anti-CD3 antibody following safety review | ||
| 17.08. | Merck KGaA lays off 20 staffers in latest blow to US research team | ||
| 17.08. | Slate Medicines uses Fulcrum Therapeutics to vault onto Nasdaq with $245M financing for migraine trials | ||
| 17.08. | Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate | ||
| 17.08. | Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague | ||
| 17.08. | AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda | ||
| 14.08. | Skye and Redx form new entity with $125M to advance fibrosis assets | ||
| 14.08. | 'We're not afraid of competition': BioCryst CEO sets out strategy after scrapping internal discovery | ||
| 14.08. | Capricor soars on plan to amend DMD filing after adcomm setback | ||
| 14.08. | MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter | ||
| 13.08. | PDS halts work on phase 3 cancer therapy to focus on colorectal contender | ||
| 13.08. | PTC's $211M bid wins Sangamo auction, teeing up 'special opportunity' to enter Fabry market | ||
| 13.08. | Cullinan tees up J&J fight-and $100M payday-as Taiho-partnered drug hits phase 3 cancer goal | ||
| 13.08. | Zealand sells its rights to Takeda's blood cancer drug for $100M ahead of FDA approval decision | ||
| 12.08. | After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on | ||
| 11.08. | Amgen lays groundwork for new R&D center in Hyderabad | ||
| 11.08. | Epicrispr raises $90M to rewrite treatment of rare muscle disease | ||
| 11.08. | Zydus' Sentynl pens $475M deal for Mereo's phase 3-ready rare genetic lung disease drug | ||
| 11.08. | Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer | ||
| 10.08. | MoonLake's nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial | ||
| 10.08. | Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies | ||
| 10.08. | Sionna's cystic fibrosis flop sends stock down 90%, but a 'significant positive' for Vertex | ||
| 10.08. | AbCellera women's health data top 'most aggressive upside scenario,' putting Astellas and Bayer on notice |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.